Hsa-miR-517-5p: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

Target Name: MIR517B

NCBI ID: G574483

MIR517B

Hsa-miR-517-5p: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

MIR517B (hsa-miR-517-5p) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker in various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study, and various studies have shown that hsa-miR-517-5p can be modulated by various therapeutic approaches, including small molecules, RNA interference, and gene editing techniques.

Hsa-miR-517-5p is a microRNA (miRNA), a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation. miRNAs are designed to target specific mRNAs for degradation by an RNA-proteasome complex, which is a complex of RNA-binding proteins and enzymes that removes the mature mRNAs from the cell. The miRNA pathway is a well-established mechanism for post-transcriptional gene regulation, and it is involved in various cellular processes, including cell growth, apoptosis, and metabolism.

The hsa-miR-517-5p molecule has a unique structure, with a length of approximately 22 nucleotides and a 19-nt non-coding region. It has a hairpin-like loop at its top and a single stem-loop at its bottom , which gives it a characteristic \"D\" shape when viewed from above. The stem-loop region has a high degree of conservation, with only a minor difference at position 16, and the loop region has a single AUG codon at position 20 , which is the start of the stem-loop.

hsa-miR-517-5p has been shown to have a variety of expressions in different tissues and cells, including the brain, pancreas, and various cancer types. It has been shown to be expressed in the brain, and its expression level has been increased in the treated groups of mice models of neurocancer. It has also been shown to be expressed in the pancreas, and its expression level has been decreased in the treated groups of pancreatic cancer cells.

hsa-miR-517-5p has been shown to play a role in various cellular processes, including cell growth, apoptosis, and metabolism. It has been shown to promote the growth of cancer cells, and to contribute to their survival. It has also has been shown to play a role in cell apoptosis, as its expression level has been shown to decrease in the treated groups of cancer cells.

hsa-miR-517-5p has been shown to be a potential drug target or biomarker in various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study, and various studies have shown that hsa- miR-517-5p can be modulated by various therapeutic approaches, including small molecules, RNA interference, and gene editing techniques.

small molecules are a popular method for modulating miRNA expression levels. various studies have shown that small molecules can be used to specifically target hsa-miR-517-5p, and to modulate its expression level. For example, one study showed that the small moleculelet -3 (SM03) can be used to inhibit the expression of hsa-miR-517-5p in cancer cells, and another study showed that the small molecule compound, RNA-conjugated interferon (siRNA), can be used to specifically target hsa -miR-517-5p in HeLa cells.

RNA interference (RNAi) is another method that can be used to modulate miRNA expression levels. RNAi is a technique that uses small interfering RNA (siRNA) to knockdown the expression of specific genes.

Protein Name: MicroRNA 517b

The "MIR517B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR517B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets